Payment overview · 2025
General Payments
$752.49
31 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Andrew Cooper, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLOWER MOUND, TX · NPI 1831120757
Verified facts
What the public records show
CMS Open Payments records show Michael Andrew Cooper, M.D. received $752.49 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.17 | 20.4% | 10 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $151.56 | 20.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $146.09 | 19.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.70 | 12.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $63.79 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.94 | 6.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.69 | 5.9% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $32.38 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.17 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $752.49 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $151.56 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.75 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.26 | 4 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $63.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.21 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.45 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.98 | 5 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 82 |
| Lisinopril | Lisinopril | 174 | 52 |
| Metformin Hcl | Metformin Hcl | 169 | 46 |
| Losartan Potassium | Losartan Potassium | 167 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 34 |
| Trazodone Hcl | Trazodone Hcl | 121 | 36 |
| Gabapentin | Gabapentin | 118 | 29 |
| Omeprazole | Omeprazole | 113 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 104 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 21 |
| Ozempic | Semaglutide | 79 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 21 |
| Allopurinol | Allopurinol | 75 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 21 |
| Sertraline Hcl | Sertraline Hcl | 69 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 15 |
| Carvedilol | Carvedilol | 63 | 18 |
| Metformin Hcl Er | Metformin Hcl | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Alendronate Sodium | Alendronate Sodium | 57 | 19 |
| Glimepiride | Glimepiride | 52 | 13 |
| Simvastatin | Simvastatin | 50 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Montelukast Sodium | Montelukast Sodium | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 13 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Prednisone | Prednisone | 14 | 14 |
| Famotidine | Famotidine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $752.49 · 31 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, Heplisav-B, INSPIRE, JARDIANCE, MOUNJARO, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR, WaveWriter Alpha Prime 16, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error